Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Non-Current Deffered Revenue (2021 - 2025)

Bolt Biotherapeutics' Non-Current Deffered Revenue history spans 5 years, with the latest figure at $2.0 million for Q3 2025.

  • For Q3 2025, Non-Current Deffered Revenue fell 49.21% year-over-year to $2.0 million; the TTM value through Sep 2025 reached $2.0 million, down 49.21%, while the annual FY2024 figure was $3.6 million, 60.25% down from the prior year.
  • Non-Current Deffered Revenue for Q3 2025 was $2.0 million at Bolt Biotherapeutics, down from $2.6 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $14.2 million in Q4 2021 and bottomed at $2.0 million in Q3 2025.
  • The 5-year median for Non-Current Deffered Revenue is $9.6 million (2023), against an average of $8.6 million.
  • The largest annual shift saw Non-Current Deffered Revenue skyrocketed 48.78% in 2022 before it plummeted 62.37% in 2024.
  • A 5-year view of Non-Current Deffered Revenue shows it stood at $14.2 million in 2021, then fell by 9.05% to $12.9 million in 2022, then fell by 29.52% to $9.1 million in 2023, then crashed by 60.25% to $3.6 million in 2024, then tumbled by 45.75% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Non-Current Deffered Revenue are $2.0 million (Q3 2025), $2.6 million (Q2 2025), and $3.0 million (Q1 2025).